Compare · ADOC vs BNTX
ADOC vs BNTX
Side-by-side comparison of Edoc Acquisition Corp. (ADOC) and BioNTech SE (BNTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADOC and BNTX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $39.34B, about 325.2x ADOC ($121.0M).
- BNTX has hit the wire 5 times in the past 4 weeks while ADOC has been quiet.
- BNTX has more recent analyst coverage (25 ratings vs 0 for ADOC).
- Company
- Edoc Acquisition Corp.
- BioNTech SE
- Price
- $2.81-63.97%
- $105.40-0.14%
- Market cap
- $121.0M
- $39.34B
- 1M return
- -
- +18.61%
- 1Y return
- -
- +1.32%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2019
- News (4w)
- 0
- 5
- Recent ratings
- 0
- 25
Edoc Acquisition Corp.
Edoc Acquisition Corp. is a blank check company. The company intends to focus on businesses primarily operating in the health care and health care provider space in North America and the Asia-Pacific. Edoc Acquisition Corp. was incorporated in 2020 and is based in Victor, New York.
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Latest ADOC
- SEC Form 15-12G filed by Edoc Acquisition Corp.
- Edoc Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- SEC Form 25-NSE filed by Edoc Acquisition Corp.
- Edoc Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 425 filed by Edoc Acquisition Corp.
- SEC Form 425 filed by Edoc Acquisition Corp.
- Edoc Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits
- Edoc Acquisition Corp. Announces Postponement Of Special Meeting Of Shareholders On Proposed Business Combination
- Edoc Acquisition Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits
- SEC Form 425 filed by Edoc Acquisition Corp.
Latest BNTX
- Chief Operating Officer Poetting Sierk sold $5,527,960 worth of Ordinary Shares (50,000 units at $110.56) (SEC Form 4)
- BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026
- Amendment: SEC Form 3 filed by new insider Sahin Ugur
- SEC Form 6-K filed by BioNTech SE
- BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
- SEC Form 6-K filed by BioNTech SE
- Amendment: SEC Form 20-F/A filed by BioNTech SE
- SEC Form 3 filed by new insider Blackwood Nicola Claire
- SEC Form 3 filed by new insider Morawietz Anja
- SEC Form 3 filed by new insider Staudigl Rudolf